A Phase 2a, Multicenter, Open-label Study to Investigate the Safety, Pharmacokinetics, and Efficacy of Combination Treatment of AL-335, Odalasvir, and Simeprevir in Japanese Subjects With Chronic Hepatitis C Genotype 1 or 2 Virus Infection, With or Without Compensated Cirrhosis Who Are Direct Acting Antiviral Treatment-naïve
Phase of Trial: Phase II
Latest Information Update: 25 Jul 2017
At a glance
- Drugs AL 335 (Primary) ; Odalasvir (Primary) ; Simeprevir (Primary)
- Indications Hepatitis C
- Focus Adverse reactions
- Sponsors Janssen Pharmaceutical KK
- 18 Jul 2017 Planned End Date changed from 9 Jan 2018 to 22 May 2018.
- 31 Jan 2017 Planned End Date changed from 1 Oct 2017 to 1 Jan 2018.
- 22 Dec 2016 Status changed from not yet recruiting to recruiting.